0001192482-18-000063.txt : 20180129
0001192482-18-000063.hdr.sgml : 20180129
20180129193810
ACCESSION NUMBER: 0001192482-18-000063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180125
FILED AS OF DATE: 20180129
DATE AS OF CHANGE: 20180129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brannelly Paul
CENTRAL INDEX KEY: 0001394936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 18557217
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 DEDHAM STREET, SUITE 800
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 780 DEDHAM STREET, SUITE 800
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-01-25
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001394936
Brannelly Paul
C/O COLLEGIUM PHARMACEUTICAL, INC.
780 DEDHAM STREET, SUITE 800
CANTON
MA
02021
0
1
0
0
Executive Vice President & CFO
Common Stock
2017-12-14
5
G
0
2000
0
D
108803
D
Common Stock
2018-01-25
4
A
0
25000
0
A
133803
D
Common Stock
2018-01-26
5
A
0
1044
10.17
A
134847
D
Stock Option (Right to Purchase)
24.35
2018-01-25
4
A
0
50000
0
A
2028-01-25
Common Stock
50000
50000
D
Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.
These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The option vests and becomes exercisable over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer.
/s/ Paul Brannelly
2018-01-29